Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Toronto

$54,000.00

NMR studies of membranes proteins & macromolecular systems

FY 2012-13

Summary
The human genome encodes over 800 G protein-coupled receptors (GPCRs) - a superfamily of membrane proteins responsible for signalling and targetted by over 50% of pharmaceuticals. We propose to develop a protocol for monitoring GPCR membrane protein misfolding and determining the binding site of pharmacophores, using 19F Nuclear Magnetic Resonance (NMR). The protocol entails new strategies for protein expression, new (19F) labeling protocols (including site-directed mutants involving parafluorphenylalanine), and approaches to determine topology and structure through inter-helix distance measurements. Most of this work will be focused on two integral membrane proteins (DAGK and V2R) which are expressed in E coli. The use of fluoro-tryptophan is key in studying misfolding and drug binding sites since tryptophans are typically located at the membrane water interface, and local chemical shift perturbations from pharamcophore binding can thus be registered. 19F shifts and relaxation rates are exquisitely sensitive to local structure and the presence of water- or membrane soluble paramagnetic additives. The combination of paramagnetic shift or rate measurements from both dissolved O2 and water soluble paramagnetic additives provides a simple way to probe local topology (immersion depth, solvent exposure, exposed surface area and local dynamics). Much of the proposed research will be bolstered by extensive membrane model studies and work with soluble proteins (ubiquitin, Mesd, calmodulin, and drkN SH3), some of which is more suited to advanced undergraduate students. Finally, an additional area of research entails new work with paramagnetic nanoparticles (NPs), consisting of gadolinium and fluorine (GdF3) and coated with polyacrylic acid. These NPs give rise to the highest known paramagnetic relaxation rates for MRI contrast agents and are directly applicable as contrast agents for Computed Tomography. Our goal is to develop the GdF3 NPs for targeted imaging and explore their potential as anticancer agents, when appropriately doped with radionuclides.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
261980-2008
Name nom
Prosser, RobertScott
Department département
Chemical and Physical Sciences (Mississauga)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2008
Award amount
54000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
26
Committee name en
Anal. & Phys. Chemistry
Committee name fr
Chimie analytique et physique
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3403
Research subject group en
Physical chemistry
Research subject group fr
Chimie physique
Research subject en
Spectroscopy
Research subject fr
Spectroscopie
Partie
5
Nb partie
5
Application title
NMR studies of membranes proteins & macromolecular systems
Keyword
NSERC
Application summary
The human genome encodes over 800 G protein-coupled receptors (GPCRs) - a superfamily of membrane proteins responsible for signalling and targetted by over 50% of pharmaceuticals. We propose to develop a protocol for monitoring GPCR membrane protein misfolding and determining the binding site of pharmacophores, using 19F Nuclear Magnetic Resonance (NMR). The protocol entails new strategies for protein expression, new (19F) labeling protocols (including site-directed mutants involving parafluorphenylalanine), and approaches to determine topology and structure through inter-helix distance measurements. Most of this work will be focused on two integral membrane proteins (DAGK and V2R) which are expressed in E coli. The use of fluoro-tryptophan is key in studying misfolding and drug binding sites since tryptophans are typically located at the membrane water interface, and local chemical shift perturbations from pharamcophore binding can thus be registered. 19F shifts and relaxation rates are exquisitely sensitive to local structure and the presence of water- or membrane soluble paramagnetic additives. The combination of paramagnetic shift or rate measurements from both dissolved O2 and water soluble paramagnetic additives provides a simple way to probe local topology (immersion depth, solvent exposure, exposed surface area and local dynamics). Much of the proposed research will be bolstered by extensive membrane model studies and work with soluble proteins (ubiquitin, Mesd, calmodulin, and drkN SH3), some of which is more suited to advanced undergraduate students. Finally, an additional area of research entails new work with paramagnetic nanoparticles (NPs), consisting of gadolinium and fluorine (GdF3) and coated with polyacrylic acid. These NPs give rise to the highest known paramagnetic relaxation rates for MRI contrast agents and are directly applicable as contrast agents for Computed Tomography. Our goal is to develop the GdF3 NPs for targeted imaging and explore their potential as anticancer agents, when appropriately doped with radionuclides.